Imazu, Miki
Fukuda, Hiroki
Kanzaki, Hideaki
Amaki, Makoto
Hasegawa, Takuya
Takahama, Hiroyuki
Hitsumoto, Tatsuro
Tsukamoto, Osamu
Morita, Toshisuke
Ito, Shin
Kitakaze, Masafumi
Funding for this research was provided by:
the Ministry of Health, Labor, and Welfare-Japan
the Ministry of Education, Culture, Sports, Science and Technology-Japan
Japan Agency for Medical Research and Development, AMED
the Japan Heart Foundation and Grants from the Japan Cardiovascular Research Foundation
the collaborative research with Kureha Corporation and Mitsubishi Tanabe Pharma Corporation
Article History
Received: 6 May 2020
Accepted: 17 September 2020
First Online: 5 October 2020
Competing interests
: H. Takahama reports grants from Banyu Life Science Foundation International, grants from The Bayer Scholarship for Cardiovascular Research. M. Amaki reports grants from Japan Heart Foundation/Bayer Yakuhin Research Grant Abroad, non-financial support from Abbott Vascular Japan, non-financial support from Takeda. T. Hasegawa reports personal fees from Takeda, Daiichi-Sankyo, Otsuka, Bayer, Tanabe-Mitsubishi, Abbott Vascular Japan, Shionogi. T. Morita reports grants from LSI medicine, AMNOS company, UNITIKA and TED company. M. M. Kitakaze reports grants from Japanese government, grants from Japan Heart Foundation, grants from Japan Cardiovascular Research Foundation, grants and personal fees from Takeda, Astellas, Sanofi, Pfizer, Novartis, Boehringer-Ingerheim, Mitsubishi-Tanabe, Kyowa-Hakko-Kirin, Abott, and Otsuka; personal fees from Daiichi-Sankyo, Ono, Bayer, from Kowa, Dainihon-Sumitomo, Sawai, MSD, Calpis, Shionogi, AstraZeneca, Asahikasei Med., Novo Nordisk, Fuji-film RI, and Japan Medical Data; grants from Nihon Kohden. The authors declare no competing interests.